Theradiag: Combined General Meeting of Shareholders of June 25, 2020 on Second Call

Voting results and resolutions

CROISSY-BEAUBOURG, France--()--Regulatory News:

THERADIAG (ISIN: FR0004197747, Ticker: ALTER) (Paris:ALTER), a company specializing in in vitro diagnostics and theranostics, informs its shareholders that its Combined General Meeting was held on second call in closed session, without shareholders or other people allowed to assist being physically present, on Thursday 25 June 2020 at 2:00 pm at the Company's registered office and chaired by Mr. Pierre Morgon, Chairman of the Board of Directors.

Following this Combined General Meeting held on second call, Theradiag informs its shareholders that the number of shares held by shareholders who voted by mail or by proxy was 2,006,369, representing a quorum of 23.218%.

Theradiag's shareholders voted all the resolutions presented in the way recommended by the Board of Directors.

The Company wishes to sincerely thank all of its shareholders for their commitment to the voting process and for their support.

The detailed voting results by resolution at this Combined General Meeting are the following:

 

Resolution n°

Resolutions

N° of votes FOR

N° of votes AGAINST

N° of ABSTENTION

Votes

%

Result of the vote

Ordinary General Meeting

1

Approval of financial statements

1 866 057

138 791

77 783

For

93.08%

Adopted

Against

6.92%

Abstention

3.74%

2

Approval of expenses and liabilities (art. 39 CGI)

1 936 613

62 644

83 374

For

96.87%

Adopted

Against

3.13%

Abstention

4.00%

3

Allocation of annual income

1 848 265

158 960

75 406

For

92.08%

Adopted

Against

7.92%

Abstention

3.62%

4

Approval of regulated agreements

1 920 199

76 400

86 032

For

96.17%

Adopted

Against

3.83%

Abstention

4.13%

5

Ratification of the appointement of Mr. Gejia OUYANG as Board member

1 761 451

216 661

104 519

For

89.05%

Adopted

Against

10.95%

Abstention

5.02%

6

Renewal of Mr. Gejia OUYANG's mandate as a Board member

1 747 573

292 034

43 024

For

85.68%

Adopted

Against

14.32%

Abstention

2.07%

7

Share buyback

1 870 677

185 527

26 427

For

90.98%

Adopted

Against

9.02%

Abstention

1.27%

 

Resolution n°

Resolutions

N° of votes FOR

N° of votes AGAINST

N° of ABSTENTION

Votes

%

Result of the vote

Extraordinary General Meeting 

8

Reduction of capital due to losses by way of a reduction in the nominal value of the shares

1 744 469

303 659

34 503

For

85.17%

Adopted

Against

14.83%

Abstention

1.66%

9

Capital increase with pre-emptive subscription rights

1 789 251

257 299

36 081

For

87.43%

Adopted

Against

12.57%

Abstention

1.73%

10

Capital increase without pre-emptive subscription rights via a public offering

1 451 041

592 962

38 628

For

70.99%

Adopted

Against

29.01%

Abstention

1.86%

11

Capital increase without pre-emptive subscription rights via a private placement

1 477 771

576 547

28 313

For

71.93%

Adopted

Against

28.07%

Abstention

1.36%

12

Capital increase without pre-emptive subscription rights for certain categories of beneficiaries

1 447 247

602 303

33 081

For

70.61%

Adopted

Against

29.39%

Abstention

1.59%

13

Increase in the number of shares by virtue of the 4 previous resolutions

1 732 927

314 650

35 054

For

84.63%

Adopted

Against

15.37%

Abstention

1.68%

14

Share purchase warrants allotment

1 598 934

447 104

36 593

For

78.15%

Adopted

Against

21.85%

Abstention

1.76%

15

Free share allotment

1 648 692

413 335

20 604

For

79.95%

Adopted

Against

20.05%

Abstention

0.98%

16

Capital increase reserved for employees

644 230

1 416 301

22 100

For

31.26%

Rejected

Against

68.74%

Abstention

1.06%

17

Setting of the global threshold

1 813 751

230 159

38 721

For

88.74%

Adopted

Against

11.26%

Abstention

1.86%

18

Reduction of the share capital via the cancellation of shares

1 831 028

216 981

34 622

For

89.40%

Adopted

Against

10.60%

Abstention

1.66%

19

Modification of the articles of association

1 791 526

240 144

50 961

For

88.18%

Adopted

Against

11.82%

Abstention

2.45%

20

Powers to carry out formalities

1 882 838

166 557

33 236

For

91.87%

Adopted

Against

8.13%

Abstention

1.60%

The minutes of this Combined General Meeting will be made available soon on the Company's website (in French): https://www.theradiag.com/en/investors/shareholder-information/general-meeting/

***

Financial calendar:
- H1 2020 revenue, Tuesday, July 21, 2020
- H1 2020 results, Monday, September 21, 2020

About Theradiag

Theradiag is the market leader in biotherapy monitoring. Capitalizing on its expertise in the diagnostics market, the Company has been developing, manufacturing and marketing innovative in vitro diagnostic (IVD) tests for over 30 years.

Theradiag pioneered “theranostics” testing (combining therapy with diagnosis), which measures the efficacy of biotherapy in the treatment of chronic inflammatory diseases. Going beyond mere diagnosis, theranostics aims to help clinicians set up “customized treatment” for each patient. This method favors the individualization of treatment, evaluation of its efficacy and the prevention of drug resistance. In response to this challenge, Theradiag develops and markets the CE-marked TRACKER® range, a comprehensive solution of inestimable medical value.

The Company is based in Marne-la-Vallée, near Paris, has operations in over 70 countries and employs over 60 people. In 2019, the Company posted revenue of €9.6 million. The Theradiag share is listed on Euronext Growth Paris (ISIN: FR0004197747) and is eligible for the French PEA-PME personal equity plan. For more information about Theradiag, please visit our website: www.theradiag.com

Contacts

Theradiag
Bertrand de Castelnau
CEO/Managing Director
Tel.: +33 (0)1 64 62 10 12
contact@theradiag.com

NewCap
Financial Communications & Investor Relations
Sandrine Boussard-Gallien
Claire Riffaud
Tel.: +33 (0)1 44 71 94 94
theradiag@newcap.eu

NewCap
Media Relations
Nicolas Mérigeau
Tel.: +33 (0)1 44 71 94 98
nmerigeau@newcap.fr

Contacts

Theradiag
Bertrand de Castelnau
CEO/Managing Director
Tel.: +33 (0)1 64 62 10 12
contact@theradiag.com

NewCap
Financial Communications & Investor Relations
Sandrine Boussard-Gallien
Claire Riffaud
Tel.: +33 (0)1 44 71 94 94
theradiag@newcap.eu

NewCap
Media Relations
Nicolas Mérigeau
Tel.: +33 (0)1 44 71 94 98
nmerigeau@newcap.fr